VSTM
NASDAQ · Biotechnology
Verastem Inc
$9.38
-0.47 (-4.77%)
Financial Highlights (FY 2026)
Revenue
49.05M
Net Income
-332,386,303
Gross Margin
82.9%
Profit Margin
-677.6%
Rev Growth
+128.2%
D/E Ratio
1.51
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 82.9% | 100.0% | 55.0% | 55.0% |
| Operating Margin | -556.2% | -1,034.6% | 4.2% | 3.8% |
| Profit Margin | -677.6% | -1,241.1% | 3.0% | 2.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 49.05M | 14.27M | 326.86M | 307.68M |
| Gross Profit | 40.64M | 14.27M | 179.63M | 169.09M |
| Operating Income | -272,836,593 | -147,629,883 | 13.85M | 11.81M |
| Net Income | -332,386,303 | -167,775,411 | 9.66M | 8.39M |
| Gross Margin | 82.9% | 100.0% | 55.0% | 55.0% |
| Operating Margin | -556.2% | -1,034.6% | 4.2% | 3.8% |
| Profit Margin | -677.6% | -1,241.1% | 3.0% | 2.7% |
| Rev Growth | +128.2% | +69.6% | +8.0% | +1.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 310.68M | 87.47M | 137.11M | 136.03M |
| Total Equity | 205.11M | 171.38M | 172.31M | 166.34M |
| D/E Ratio | 1.51 | 0.51 | 0.80 | 0.82 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -272,855,248 | -176,249,033 | 19.14M | 17.15M |
| Free Cash Flow | — | — | 10.52M | 8.69M |